Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In 2001, we proposed to restore this balance using judicious doses of antiangiogenic agents and suggested that this strategy would transiently give rise to tumour vessels with structural and functional phenotypes closer to those of the vessels of nonmalignant tissues — a state we referred to as ‘normalized’ (REF. 61)”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [61]
In the citing paper
“We also suggested that the use of other therapies during this ‘window of normalization’ (REF. 61) would result in better outcomes than if the same agents were given before or after this window.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [61]
In the citing paper
“Traditional angiogenesis inhibitors mainly block VEGF signaling and prune rather than eradicate tumor vessels.”
From Hypoxia signaling in cancer: Implications for therapeutic interventions (2023) · cites this paper as [78]
Citations
Cites
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070 · cited 1×
“What mechanisms are responsible for this normalization? How can we exploit them? This knowledge will affect the treatment not only of cancer but also of other diseases characterized by abnormal vasculature—such as hemangiomas, arteriovenous malformations, diabetic retinopathy and macular degeneration—for which anti-an…”
BackgroundSelf-citationGenes Expressed in Human Tumor Endothelium
Croix, B. S., Rago, C., Velculescu, V., Traverso, G., Romans, K. E., Montgomery, E., Lal, A., Riggins, G. J., Lengauer, C., Vogelstein, B., et al. (2000) · Science · doi:10.1126/science.289.5482.1197 · Cited by 1,845
Browder, T. D., Butterfield, C., Kräling, B. M., Shi, B., Marshall, B., OʼReilly, M., & Folkman, J. (2000) · PubMed · Cited by 1,720
Benjamin, L. E., Golijanin, D., Itin, A., Pode, D., & Keshet, E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5028 · Cited by 1,241
Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., & Kerbel, R. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8829 · Cited by 1,168
Barriers to Drug Delivery in Solid Tumors
Jain, R. K. (1994) · Scientific American · doi:10.1038/scientificamerican0794-58 · Cited by 1,069
Self-citationLee, C. G., Heijn, M., di Tomaso, E., Griffon, G., Ancukiewicz, M., Koike, C., Park, K. R., Ferrara, N., Jain, R. K., Suit, H. D., et al. (2000) · PubMed · Cited by 733
Self-citationYuan, F., Chen, Y., Dellian, M., Safabakhsh, N., Ferrara, N., & Jain, R. K. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.25.14765 · Cited by 719
Self-citationBaish, J. W., & Jain, R. K. (2000) · PubMed · Cited by 714
Self-citationThe next frontier of molecular medicine: Delivery of therapeutics
Jain, R. K. (1998) · Nature Medicine · doi:10.1038/nm0698-655 · Cited by 407
Self-citation
Research works printed but not linked: 6
- Folkman, J. in Harrison's Textbook of Internal Medicine, 15th ed. (eds Braunwald, E. et al.) 517–530 (McGraw-Hill, New York, 2001).
- Kozin, S.V. et al. VEGF receptor-2 blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res. 61, 39–44 (2001).
- Tsuzuki, Y. et al. VEGF modulation by targeting HIF-1α→HRE→VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Research 60, 6248–6252 (2000).
- Kadambi, A. et al. Vascular endothelial growth factor (VEGF)–C differentially affects tumor vascular function and leukocyte recruitment. Cancer Res. 61, 2404–2408 (2001).
- Lee, C.G. et al. Anti-VEGF treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 60, 5565–5570 (2000).
- Hansen-Algenstaedt, N. et al. Tumor oxygenation during VEGFR-2 blockade, hormone ablation, and chemotherapy. Cancer Res. 60, 4556–4560 (2000).
Cited by
Items 401–500 of 1,004
Thairu, N., Kiriakidis, S., Dawson, P., & Paleolog, E. M. (2011) · Angiogenesis · doi:10.1007/s10456-011-9208-2 · Cited by 95
Sonveaux, P., Dessy, C., Brouet, A., Jordan, B. F., Grégoire, V., Gallez, B., Balligand, J., & Feron, O. (2002) · The FASEB Journal · doi:10.1096/fj.02-0487fje · Cited by 89
Zhang, J., Wang, S., Guo, X., Lu, Y., Liu, X., Jiang, M., Li, X., Qin, B., Luo, Z., Liu, H., et al. (2022) · ACS Nano · doi:10.1021/acsnano.2c05408 · Cited by 91
Tumour-associated vasculature in T cell homing and immunity: opportunities for cancer therapy
Lanitis, E., Irving, M. B., & Coukos, G. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01187-w · Cited by 97
Narayana, A., Golfinos, J. G., Fischer, I., Raza, S., Kelly, P., Parker, E. C., Knopp, E. A., Medabalmi, P., Zagzag, D., Eagan, P., et al. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.05.062 · Cited by 91
Nagai, T., Sato, M., Kutsuna, T., Kokubo, M., Ebihara, G., Ohta, N., & Mochida, J. (2010) · Arthritis Research & Therapy · doi:10.1186/ar3142 · Cited by 90
Marcucci, F., & Corti, A. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.09.007 · Cited by 95
Zhang, M., Ye, J.-J., Xia, Y., Wang, Z.-Y., Li, C.-X., Wang, X.-S., Yu, W., Song, W., Feng, J., & Zhang, X.-Z. (2019) · ACS Nano · doi:10.1021/acsnano.9b07330 · Cited by 89
Normalization of Tumor Vasculature by Oxygen Microbubbles with Ultrasound
Ho, Y.-J., Chu, S.-W., Liao, E., Fan, C., Chan, H., Wei, K., & Yeh, C. (2019) · Theranostics · doi:10.7150/thno.37750 · Cited by 92
Vives, M., Morell, M., Gracova, K., Graupera, M., Casanovas, O., Capellá, G., Serrano, T., Laquente, B., & Viñals, F. (2013) · International Journal of Cancer · doi:10.1002/ijc.28259 · Cited by 95
Bevacizumab in the Treatment of Metastatic Breast Cancer: Friend or Foe?
Montero, A. J., Escobar, M., Lopes, G. D. L., Jr., Glück, S., & Vogel, C. L. (2011) · Current Oncology Reports · doi:10.1007/s11912-011-0202-z · Cited by 89
Coriat, R., Ropert, S., Mir, O., Billemont, B., Chaussade, S., Massault, P. P., Blanchet, B., Vignaux, O., & Goldwasser, F. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9458-7 · Cited by 88
Thermographic assessment of tumor growth in mouse xenografts
Song, C., Appleyard, V. C. L., Murray, K. E., Frank, T., Sibbett, W., Cuschieri, A., & Thompson, A. M. (2007) · International Journal of Cancer · doi:10.1002/ijc.22808 · Cited by 88
Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy
Reardon, D. A., Wen, P. Y., Desjardins, A., Batchelor, T. T., & Vredenburgh, J. J. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.4.541 · Cited by 93
Erlotinib and Bevacizumab Have Synergistic Activity against Melanoma
Schicher, N., Paulitschke, V., Swoboda, A., Kunstfeld, R., Loewe, R. P., Pilarski, P., Pehamberger, H., & Höeller, C. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2407 · Cited by 88
Faruque, L. I., Lin, M., Battistella, M., Wiebe, N., Reiman, T., Hemmelgarn, B. R., Thomas, C. M., & Tonelli, M. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101145 · Cited by 87
Vascular remodeling and clinical resistance to antiangiogenic cancer therapy
GLADEBENDER, J., COONEY, E., KANDEL, J., & Yamashiro, D. J. (2004) · Drug Resistance Updates · doi:10.1016/j.drup.2004.09.001 · Cited by 99
Cham, K. K. Y., Baker, J. H. E., Takhar, K. S., Flexman, J. A., Wong, M. Q., Owen, D. A., Yung, A., Kozlowski, P., Reinsberg, S. A., Chu, E. M., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605727 · Cited by 87
Ma, J., Li, S., Reed, K., Guo, P., & Gallo, J. M. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.048587 · Cited by 87
Diosmetin inhibits tumor development and block tumor angiogenesis in skin cancer
Choi, J., Lee, D.-H., Park, S., & Seol, J. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109091 · Cited by 87
Optimizing the Delivery of Cancer Drugs That Block Angiogenesis
Cao, Y., & Langer, R. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000399 · Cited by 89
Janji, B., Berchem, G., & Chouaïb, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00887 · Cited by 88
Uniform Overexpression and Rapid Accessibility of α5β1 Integrin on Blood Vessels in Tumors
Parsons‐Wingerter, P. A., Kasman, I. M., Norberg, S. M., Magnussen, A., Zanivan, S. R., Rissone, A., Bałuk, P., Favre, C., Jeffry, U. B., Murray, R., et al. (2005) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62965-3 · Cited by 88
Pinho, S. T. R., Bacelar, F. S., Andrade, R. F. S., & Freedman, H. I. (2012) · Nonlinear Analysis Real World Applications · doi:10.1016/j.nonrwa.2012.07.034 · Cited by 85
Gastric cancer and the epoch of immunotherapy approaches
Niccolai, E., Taddei, A., Prisco, D., & Amedei, A. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i19.5778 · Cited by 88
Role of genetic polymorphisms in tumour angiogenesis
Balasubramanian, S. P., Brown, N. J., & Reed, M. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600625 · Cited by 92
Manipulation of immune‒vascular crosstalk: new strategies towards cancer treatment
Zhao, Y., Yu, X., & Li, J. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.09.014 · Cited by 84
Li, S., Chen, J. Y., & Sun, Z. (2021) · 癌症:英文版 · doi:10.1002/cac2.12183 · Cited by 87
Challenges for patient selection with VEGF inhibitors
Longo, R., & Gasparini, G. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0403-6 · Cited by 88
Chung, W.-S., Park, M., Shin, S. J., Baek, S., Kim, Y.-E., Choi, J., & Kim, M. (2012) · American Journal of Roentgenology · doi:10.2214/ajr.11.7910 · Cited by 84
Böckelmann, L. C., & Schumacher, U. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1702974 · Cited by 72
Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives
Eichhorn, M., Strieth, S., & Dellian, M. (2004) · Drug Resistance Updates · doi:10.1016/j.drup.2004.03.001 · Cited by 94
Tumors vs. Chronic Wounds: An Immune Cell's Perspective
Hua, Y., & Bergers, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02178 · Cited by 89
Angiogenesis and antiangiogenic agents in cervical cancer
Tomao, F., Tomao, F., Rossi, L., Zaccarelli, E., Caruso, D., Zoratto, F., Panici, P. B., & Papa, A. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s68286 · Cited by 83
Analyzing attributes of vessel populations
Bullitt, E., MULLER, K., Jung, I., Lin, W., & Aylward, S. (2004) · Medical Image Analysis · doi:10.1016/j.media.2004.06.024 · Cited by 83
Guadagni, F., Ferroni, P., Palmirotta, R., Portarena, I., Formica, V., & Roselli, M. (2007) · PubMed · Cited by 92
Wang, W.-Q., Liu, L., Xu, H.-X., Luo, G.-P., Chen, T., Wu, C.-T., Xu, Y.-F., Xu, J., Liu, C., Zhang, B., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071189 · Cited by 75
Endothelial YAP/TAZ Signaling in Angiogenesis and Tumor Vasculature
Hooglugt, A., van der Stoel, M. M., Boon, R. A., & Huveneers, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.612802 · Cited by 82
Schefter, T. E., Winter, K. A., Kwon, J. S., Stuhr, K. A., Balaraj, K. S., Yaremko, B., Small, W. C., & Gaffney, D. K. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2011.10.060 · Cited by 82
Zhu, A. X. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.05.014 · Cited by 82
Insight On Colorectal Carcinoma Infiltration by Studying Perilesional Extracellular Matrix
Nebuloni, M., Albarello, L., Andolfo, A., Magagnotti, C., Genovese, L., Locatelli, I., Tonon, G., Longhi, E., Zerbi, P., Allevi, R., et al. (2016) · Scientific Reports · doi:10.1038/srep22522 · Cited by 91
Novel chemotherapy regimens for advanced lung cancer: have we reached a plateau?
Baxevanos, P., & Mountzios, G. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.04.04 · Cited by 82
Concurrent Binding and Delivery of Proteins and Lipophilic Small Molecules Using Polymeric Nanogels
González-Toro, D. C., Ryu, J.-H., Chacko, R. T., Zhuang, J., & Thayumanavan, S. (2012) · Journal of the American Chemical Society · doi:10.1021/ja3019143 · Cited by 80
Vascular Endothelial Growth Factor A Inhibition in Gastric Cancer
Park, D. J., Thomas, N. J., Yoon, C., & Yoon, S. S. (2014) · Gastric Cancer · doi:10.1007/s10120-014-0397-4 · Cited by 93
Lin, M. I., & Sessa, W. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.12.003 · Cited by 94
Williams, L. E., DeNardo, G. L., & Meredith, R. F. (2008) · Medical Physics · doi:10.1118/1.2938520 · Cited by 89
Current Progress in Targeted Therapy for Colorectal Cancer
Ortega, J., Vigil, C. E., & Chodkiewicz, C. (2010) · Cancer Control · doi:10.1177/107327481001700102 · Cited by 85
Tian, F., Dahmani, F. Z., Qiao, J., Jiang, N., Xiong, H., Liu, T., Zhou, J., & Yao, J. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.05.050 · Cited by 80
Vascular normalization in immunotherapy: A promising mechanisms combined with radiotherapy
Liu, Z., Zhao, Q., Zheng, Z., Liu, S., Meng, L., Dong, L., & Jiang, X. M. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111607 · Cited by 83
Aspriţoiu, V. M., Stoica, I., Bleoţu, C., & Diaconu, C. C. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.689962 · Cited by 90
Clinically approved combination immunotherapy: Current status, limitations, and future perspective
Lu, L., Zhan, M., Li, X.-Y., Zhang, H., Dauphars, D. J., Jiang, J., Yin, H., Li, S., Luo, S., Li, Y., et al. (2022) · Current Research in Immunology · doi:10.1016/j.crimmu.2022.05.003 · Cited by 86
Zhang, L., Hannay, J. A. F., Liu, J., Das, P. K., Zhan, M., Nguyen, T. P. T., Hicklin, D. J., Yu, D., Pollock, R. E., & Lev, D. C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1217 · Cited by 86
Targeting angiogenesis in head and neck cancer
Vassilakopoulou, M., Psyrri, A. K., & Argiris, A. E. (2015) · Oral Oncology · doi:10.1016/j.oraloncology.2015.01.006 · Cited by 85
de Castro, G., Puglisi, F., de Azambuja, E., Saghir, N. S. E., & Awada, A. H. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.02.007 · Cited by 80
Segers, J., Fazio, V. D., Ansiaux, R., Martinive, P., Féron, O., Wallemacq, P. E., & Gallez, B. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.12.017 · Cited by 82
Sorg, B. S., Hardee, M. E., Agarwal, N., Moeller, B. J., & Dewhirst, M. W. (2008) · Journal of Biomedical Optics · doi:10.1117/1.2837439 · Cited by 75
Li, W., Li, X., Liu, S., Yang, W., Pan, F., Yang, X.-Y., Du, B., Qin, L., & Pan, Y. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s128802 · Cited by 77
Zhong, W., Yang, W., Qin, Y., Gu, W., Xue, Y., Tang, Y., Xu, H., Wang, H., Zhang, C., Wang, C., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1291-z · Cited by 83
Romano, V., Belviso, I., Venuta, A., Ruocco, M. R., Masone, S., Aliotta, F., Fiume, G., Montagnani, S., Avagliano, A., & Arcucci, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105283 · Cited by 83
Nanomedicines Targeting the Tumor Microenvironment
Tong, R., & Langer, R. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000123 · Cited by 80
Martin, L. P., & Schilder, R. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.1088 · Cited by 86
Cesca, M., Bizzaro, F., Zucchetti, M., & Giavazzi, R. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00259 · Cited by 75
Seo, B. R., DelNero, P., & Fischbach, C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.011 · Cited by 74
Yang, Z., Chen, J., Yao, J., Lin, R., Meng, J., Liu, C., Yang, J., Li, X., Wang, L. V., & Song, L. (2014) · Optics Express · doi:10.1364/oe.22.001500 · Cited by 78
Bahri, S., Chen, J.-H., Mehta, R. S., Carpenter, P. M., Nie, K., Kwon, S. Y., Yu, H. J., Nalcioğlu, O., & Su, M. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0441-5 · Cited by 77
Sano, D., Matsumoto, F., Valdecanas, D. R., Zhao, M., Molkentine, D. P., Takahashi, Y., Hanna, E. Y., Papadimitrakopoulou, V., Heymach, J. V., Milas, L., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2120 · Cited by 77
Innovations in Chemotherapy for Metastatic Colorectal Cancer: An Update of Recent Clinical Trials
O’Neil, B. H., & Goldberg, R. M. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0083 · Cited by 84
Explant Outgrowth, Propagation and Characterization of Human Pericytes
Maier, C. L., Shepherd, B. R., Yi, T., & Pober, J. S. (2010) · Microcirculation · doi:10.1111/j.1549-8719.2010.00038.x · Cited by 76
Coscas, F., Lupidi, M., Boulet, J. F., Sellam, A., Cabral, D., Serra, R., Français, C., Souied, E. H., & COSCAS, G. J. (2018) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2018-313065 · Cited by 76
Levy, A., Krailo, M., Chi, S. N., Villaluna, D., Springer, L., Williams‐Hughes, C., Fouladi, M., & Gajjar, A. J. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.29031 · Cited by 76
Emerging roles for contrast-enhanced ultrasound
Weskott, H. P. (2008) · Clinical Hemorheology and Microcirculation · doi:10.3233/ch-2008-1062 · Cited by 75
Liao, S., Liu, J., Lin, P., Shi, T., Jain, R. K., & Xu, L. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2429 · Cited by 73
Self-citationQuesada, A. J., Nelius, T., Yap, R. X. J., Zaichuk, T. A., Alfranca, A., Filleur, S., Volpert, O. V., & Redondo, J. M. (2005) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401615 · Cited by 78
Antiangiogenic therapy in brain tumors
Lakka, S. S., & Rao, J. S. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.10.1457 · Cited by 80
Folarin, A., Konerding, M. A., TIMONEN, J., Nagl, S., & Pedley, R. B. (2010) · Microvascular Research · doi:10.1016/j.mvr.2010.03.007 · Cited by 82
History and conceptual developments in vascular biology and angiogenesis research: a personal view
Bikfalvi, A. (2017) · Angiogenesis · doi:10.1007/s10456-017-9569-2 · Cited by 79
Molecular approach to breast cancer treatment
Yarden, Y., Baselga, J. M., & Miles, D. W. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.07.016 · Cited by 75
Ribba, B., Watkin, E., Tod, M. M., Girard, P., Grenier, E., You, B., Giraudo, E., & Freyer, G. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.10.003 · Cited by 74
Old Player-New Tricks: Non Angiogenic Effects of the VEGF/VEGFR Pathway in Cancer
Ntellas, P., Mavroeidis, L., Gκoura, S., Gazouli, I., Amylidi, A.-L., Papadaki, A., Zarkavelis, G., Mauri, D., Karpathiou, G., Kolettas, E., et al. (2020) · Cancers · doi:10.3390/cancers12113145 · Cited by 76
Olson, P., Chu, G. C., Perry, S. R., Nolan-Stevaux, O., & Hanahan, D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111079108 · Cited by 73
Synergistic antiglioma activity of radiotherapy and enzastaurin
Tabatabai, G., Frank, B., Wick, A., Lemke, D., von Kürthy, G., Obermüller, U., Heckl, S., Christ, G., Weller, M., & Wick, W. (2007) · Annals of Neurology · doi:10.1002/ana.21057 · Cited by 74
Dynamics of tumor growth and combination of anti-angiogenic and cytotoxic therapies
Kohandel, M., Kardar, M., Milosevic, M., & Sivaloganathan, S. (2007) · Physics in Medicine and Biology · doi:10.1088/0031-9155/52/13/001 · Cited by 82
Kobori, T., Hamasaki, S., Kitaura, A., Yamazaki, Y., Nishinaka, T., Niwa, A., Nakao, S., Wake, H., Mori, S., Yoshino, T., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00334 · Cited by 77
Measuring tumour vascular response to antivascular and antiangiogenic drugs
Tozer, G. M. (2003) · British Journal of Radiology · doi:10.1259/bjr/30165281 · Cited by 74
Blood pressure control and diabetic retinopathy
Klein, R., & Klein, B. E. K. (2002) · British Journal of Ophthalmology · doi:10.1136/bjo.86.4.365 · Cited by 82
Myers, A. L., Williams, R. F., Ng, C., Hartwich, J. E., & Davidoff, A. M. (2010) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2010.02.068 · Cited by 73
Yalçın, Ş., Uslu, R., Dane, F., Yılmaz, U., Zengin, N., Büyükünal, E., Buyukberber, S., Camcı, C., Şencan, O., Kılıçkap, S., et al. (2013) · Oncology · doi:10.1159/000355914 · Cited by 76
Lawrence, Y. R., Vikram, B., Dignam, J. J., Chakravarti, A., Machtay, M. X., Freidlin, B., Takebe, N., Curran, W. J., Bentzen, S. M., Okunieff, P. G., et al. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs472 · Cited by 74
LRG1 destabilizes tumor vessels and restricts immunotherapeutic potency
O’Connor, M. N., Kallenberg, D. M., Camilli, C., Pilotti, C., Dritsoula, A., Jackstadt, R., Bowers, C., Watson, H. A., Alatsatianos, M., Ohme, J., et al. (2021) · Med · doi:10.1016/j.medj.2021.10.002 · Cited by 73
Ishiwatari, H., Sato, Y., Murase, K., Yoneda, A., Fujita, R., Nishita, H., Birukawa, N. K., Hayashi, T., Sato, T., Miyanishi, K., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301746 · Cited by 72
Drug inhibition of angiogenesis
Madhusudan, S., & Harris, A. L. (2002) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(02)00184-4 · Cited by 81
Barriers to Drug Delivery in Interventional Oncology
Sheth, R. A., Hesketh, R., Kong, D. S., Wicky, S., & Öklü, R. (2013) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2013.03.034 · Cited by 73
Angiogenesis in melanoma: an update with a focus on current targeted therapies
Jour, G., Ivan, D. S., & Aung, P. P. (2016) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2015-203482 · Cited by 75
Aghanejad, A., Bonab, S. F., Sepehri, M., Haghighi, F. S., Tarighatnia, A., Kreiter, C., Nader, N. D., & Tohidkia, M. R. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.03.057 · Cited by 74
Optimized strategies of ROS-based nanodynamic therapies for tumor theranostics
Di, Y., Deng, R., Liu, Z., Mao, Y., Gao, Y., Zhao, Q., & Wang, S. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122391 · Cited by 72
A New Target for Tumor Therapy
Jain, R. K. (2009) · New England Journal of Medicine · doi:10.1056/nejmcibr0902054 · Cited by 75
Self-citationSolving the Puzzle of Metastasis: The Evolution of Cell Migration in Neoplasms
Chen, J., Sprouffske, K., Huang, Q., & Maley, C. C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017933 · Cited by 73
O’Reilly, T., Wartmann, M., Brueggen, J., ALLEGRINI, P. R., Floersheimer, A., Maira, S.-M., & McSheehy, P. M. J. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0695-9 · Cited by 71
Ryan, C. J., Stadler, W. M., Roth, B. J., Hutcheon, D., Conry, S., Puchalski, T. A., Morris, C. Q., & Small, E. J. (2007) · Investigational New Drugs · doi:10.1007/s10637-007-9050-y · Cited by 71
Enhancement of radiation response with bevacizumab
HOANG, T. N., Huang, S., Armstrong, E. A., Eickhoff, J. C., & Harari, P. M. (2012) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-31-37 · Cited by 71
Metadata
- Authors
- Jain, R. K.
- Affiliations
- Harvard University (US)
- Corresponding author
- Jain, Rakesh K.
- Venue
- Nature Medicine
- Published
- 2001-09
- Volume
- 7
- Issue
- 9
- Pages
- 987-989
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W1603230122
- Cited by
- 2,184
- References
- 26
- Citations by year
- 2026: 58 · 2025: 65 · 2024: 61 · 2023: 88 · 2022: 97 · 2021: 91 · 2020: 93 · 2019: 91 · 2018: 69 · 2017: 94 · 2016: 82 · 2015: 106 · 2014: 94 · 2013: 101 · 2012: 124
- FWCI
- 16.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- anti-angiogenic therapy, tumor vasculature normalization, solid tumors, cancer prevention, combination therapy, drug delivery to tumors, tumor vasculature
- MeSH terms
- Blood Vessels, Clinical Trials as Topic, Humans, Neoplasms, Neovascularization, Pathologic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.